TELA Bio Q2 revenue down 4% to $19.3M, withdraws FY2026 guidance

TELA Bio, Inc.

Q2 2026 revenue $19.3M, down 4% from $20.2M; gross margin 72% vs 70%.
Net loss widened to $11.3M from $9.9M; operating loss $9.3M; cash $30.4M.
Heather Getz appointed CEO and Director effective August 4, 2026.
International revenue up 26%, OviTex units up 12%, LiquiFix revenue up 39% YoY.
Full-year 2026 revenue guidance withdrawn; company cites PRS volume decline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.